Stock analysis, trade plans, and proprietary indicators by Trend Edge.
Trend Edge Setup Score
Trend Edge rates CRNX Bullish with a Setup Score of 0, net conviction 30, actionability 0. How the Setup Score works →
Total Setup Score
0
Directional Bias
Bullish
Net Conviction
30
Actionability
0 (extended)
Key signals behind this score
40wk Uptrend — rising+above (sma 42.98 vs px 83.62)
200wk Uptrend — rising+above (sma 35.19 vs px 83.62)
Short Squeeze Setup — velZ +0.90 · age 31w×0.95 · 13.45%
Founder-Led — founder/CEO led
About Crinetics Pharmaceuticals Inc
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in a Phase 3 clinical trial for the treatment of acromegaly and carcinoid syndrome associated with neuroen… Read full Trend Edge analysis →
Sector: Healthcare
Industry: Biotechnology
Exchange: NASDAQ
IPO Date: July 18, 2018
Headquarters: 6055 Lusk Boulevard, San Diego, CA, United States, 92121
Founder-Led: Yes — Scott Struthers (Founder, President, CEO & Director), Stephen F. Betz (Co-Founder & Chief Scientific Officer)
Key Metrics
Current Price
$83.58
Market Cap
$8.85B
Float
95.5M
Shares Outstanding
105.8M
Price/Sales (TTM)
489.81
vs. Analyst Target
-1.3% to analyst PT
Operating Margin (TTM)
-1307.79%
Revenue (TTM)
$18.1M
Dividend Rate
None
Analyst Target Price
$82.50 (17 analysts)
Financial History
Annual Revenue & Earnings History
Year
Revenue
Net Income
Gross Profit
EBITDA
2020
$71,000
-$72.9M
$71,000
-$74.0M
2021
$1.1M
-$107M
$1.1M
-$107M
2022
$4.7M
-$160M
$4.7M
-$167M
2023
$4.0M
-$215M
$4.0M
-$213M
2024
$1.0M
-$298M
$1.0M
-$296M
2025
$7.7M
-$465M
$6.6M
-$461M
Recent Quarterly Revenue & Net Income
Quarter
Revenue
Net Income
Jun 2025
$1.0M
-$116M
Sep 2025
$143,000
-$130M
Dec 2025
$6.2M
-$123M
Mar 2026
$10.7M
-$128M
Ownership & Float
Insider Ownership
1.6%
Institutional Ownership
119.8%
Short Float
13.5%
% of All Funds Holding
2.74%
Number of Funds Holding
225
Current Moving Averages
Trend Edge tracks near-term, medium-term, cyclical, and secular moving averages across weekly and monthly timeframes to identify trend structure at every horizon.
Timeframe
SMA
Value
Trend Context
Weekly
10-Week SMA
$41.24
Near-term / short-term trend
Weekly
40-Week SMA
$42.98
Medium-term trend
Weekly
80-Week SMA
$38.41
Cyclical trend (business cycle)
Weekly
200-Week SMA
$35.19
Secular trend (multi-year)
Monthly
10-Month SMA
$45.83
Near-term monthly trend
Monthly
20-Month SMA
$40.65
Medium-term monthly trend
Monthly
40-Month SMA
$39.07
Secular monthly trend
Volume Shelves — Support & Resistance
Trend Edge identifies volume shelves: price zones where historically elevated trading volume
creates structural support or resistance. A volume shelf forms when a disproportionate share of cumulative
volume was transacted at a specific price level, making it a high-conviction anchor for future price reactions.
Price Level
Type
Volume Ratio
Age
$37.50
support
3.45x
0 months ago
$31.10
support
1.94x
9 months ago
Historical Earnings Reactions (32 events)
Timeframe
Avg Return
Median
Win Rate
Best
Worst
Gap
1.15%
1.05%
68.75%
10.00%
-7.89%
1 Day
0.22%
-1.03%
43.75%
15.53%
-13.82%
1 Week
3.74%
2.24%
59.38%
25.40%
-29.96%
2 Weeks
2.26%
1.74%
53.13%
39.49%
-22.68%
1 Month
3.40%
0.00%
48.39%
50.75%
-27.22%
Next earnings: August 4, 2026 (24 days away)
Seasonality & Day-of-Week Patterns
Monthly Seasonality
Month
Avg Return
Win Rate
Samples
Jan
-7.8%
50.0%
8
Feb
-2.2%
50.0%
8
Mar
-5.7%
25.0%
8
Apr
6.9%
62.5%
8
May
-2.6%
50.0%
8
Jun
0.5%
62.5%
8
Jul
-2.5%
42.9%
7
Aug
5.5%
50.0%
8
Sep
10.5%
37.5%
8
Oct
0.7%
50.0%
8
Nov
10.5%
87.5%
8
Dec
3.7%
75.0%
8
Day-of-Week Tendencies
Day
Avg Return
Win Rate
Samples
Monday
0.04%
47.1%
376
Tuesday
0.35%
51.7%
412
Wednesday
0.31%
52.6%
409
Thursday
-0.03%
47.8%
402
Friday
-0.15%
45.6%
401
Top Institutional Holders
Institutional holder breakdown coming soon.
Total institutional ownership: 119.8%
Insider Transactions — Smart Summary
Total insider ownership: 1.6%
Founder-led management: Scott Struthers (Founder, President, CEO & Director), Stephen F. Betz (Co-Founder & Chief Scientific Officer)
Trend Edge's AI Consult feature delivers a comprehensive, multi-layer trade plan for Crinetics Pharmaceuticals Inc
(CRNX) powered by Claude Opus — Anthropic's most capable AI model.
The analysis covers five layers:
technical analysis (near-term, medium-term, cyclical, and secular trend, momentum,
volume shelf support and resistance, breakout and breakdown signals),
qualitative analysis (business model, competitive moat, sector dynamics),
insider sentiment (buy and sell signals from executive and director transactions),
share stats analysis (institutional accumulation, fund positioning, short float squeeze potential), and
fundamental analysis (valuation, revenue growth, profit margin, earnings quality).
AI Consult synthesizes all five layers into a single bullish or bearish thesis with explicit entry, exit,
stop loss, and take profit levels — giving you a complete, AI-powered trade plan with defined risk/reward.
Whether you are building a long position, initiating a short, or looking for a reversal setup,
AI Consult identifies the highest-probability signal from the current trend.